查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153335

全球癌症基因治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Cancer Gene Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球癌症基因治療市場預計將從2025年的61.6億美元成長至2034年的298.6億美元，並預計在2026年至2034年間以19.17%的複合年成長率成長。分子生物學和基因工程的進步正推動全球癌症基因治療市場快速成長。全球癌症發生率的不斷上升加速了創新療法的研究。基因療法透過修飾或替換缺陷基因提供標靶解決方案，從而提高治療的精準度。對癌症研究和臨床試驗投入的增加也顯著促進了市場發展。

關鍵成長要素包括病毒載體技術和基於CRISPR的基因編輯工具的突破性進展。個人化醫療的日益普及正在推動基因治療的需求。新基因療法的法規核准進一步促進了創新。此外，生技公司與研究機構之間的合作正在加速產品商業化和市場擴張。

預計未來市場將持續成長，這主要得益於遞送系統和安全性的不斷進步。公眾意識的提高和報銷機制的完善將促進其普及。新興市場不斷完善的癌症治療基礎設施也帶來了新的機會。隨著基因編輯技術的不斷進步，癌症基因療法有望成為癌症治療領域的變革性力量。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球癌症基因治療市場：依治療方法分類

  • 市場分析、洞察與預測
  • 溶瘤病毒療法
  • 基因誘導免疫療法
  • 基因轉移

第5章 全球癌症基因治療市場：依最終用途分類

  • 市場分析、洞察與預測
  • 研究機構
  • 生物製藥公司
  • 診斷中心
  • 其他

第6章 全球癌症基因治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novartis
    • Gilead Sciences/Kite Pharma
    • Bristol Myers Squibb
    • Johnson & Johnson/Legend Biotech
    • Roche
    • AstraZeneca
    • Pfizer
    • BioMarin Pharmaceutical
    • Sarepta Therapeutics
    • Bluebird Bio
    • CRISPR Therapeutics
    • Vertex Pharmaceuticals
    • Intellia Therapeutics
    • REGENXBIO
    • Audentes/Astellas Gene Therapies
    • Rocket Pharmaceuticals
    • Krystal Biotech
    • Adaptimmune
    • Iovance Biotherapeutics
    • Cellectis
簡介目錄
Product Code: VMR112114339

The global cancer gene therapy market size is expected to reach USD 29.86 Billion in 2034 from USD 6.16 Billion in 2025, growing at a CAGR of 19.17% during 2026-2034.The Global Cancer Gene Therapy Market is witnessing rapid growth due to advancements in molecular biology and genetic engineering. Increasing prevalence of cancer worldwide has accelerated research in innovative treatment approaches. Gene therapy offers targeted solutions by modifying or replacing defective genes, improving treatment precision. Rising investments in oncology research and clinical trials are significantly supporting market development.

Key growth drivers include breakthroughs in viral vector technology and CRISPR-based gene editing tools. Expanding adoption of personalized medicine enhances the demand for gene-based therapies. Regulatory approvals of novel gene therapies encourage further innovation. Additionally, collaborations between biotechnology firms and research institutions accelerate product commercialization and market expansion.

Looking ahead, the market is expected to grow with ongoing advancements in delivery systems and safety profiles. Increased awareness and improved reimbursement frameworks will facilitate adoption. Emerging markets with expanding oncology infrastructure present new opportunities. As research continues to refine gene-editing technologies, cancer gene therapy is poised to become a transformative force in oncology treatment.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product Therapy

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer

By End Use

  • Research Institutes
  • Biopharmaceutical Companies
  • Diagnostic Centers
  • Others

COMPANIES PROFILED

  • Novartis, Gilead Sciences/Kite Pharma, Bristol Myers Squibb, Johnson & Johnson/Legend Biotech, Roche, AstraZeneca, Pfizer, BioMarin Pharmaceutical, Sarepta Therapeutics, bluebird bio, CRISPR Therapeutics, Vertex Pharmaceuticals, Intellia Therapeutics, REGENXBIO, Audentes/Astellas Gene Therapies, Rocket Pharmaceuticals, Krystal Biotech, Adaptimmune, Iovance Biotherapeutics, Cellectis

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER GENE THERAPY MARKET: BY PRODUCT THERAPY 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product Therapy
  • 4.2. Oncolytic Virotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Gene Induced Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Gene Transfer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER GENE THERAPY MARKET: BY END USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End Use
  • 5.2. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER GENE THERAPY MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Product Therapy
    • 6.2.2 By End Use
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Product Therapy
    • 6.3.2 By End Use
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Spain
    • 6.3.8 Russia
    • 6.3.9 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Product Therapy
    • 6.4.2 By End Use
    • 6.4.3 China
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 India
    • 6.4.7 Australia
    • 6.4.8 South East Asia
    • 6.4.9 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Product Therapy
    • 6.5.2 By End Use
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Product Therapy
    • 6.6.2 By End Use
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CANCER GENE THERAPY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Novartis
    • 8.2.2 Gilead Sciences/Kite Pharma
    • 8.2.3 Bristol Myers Squibb
    • 8.2.4 Johnson & Johnson/Legend Biotech
    • 8.2.5 Roche
    • 8.2.6 AstraZeneca
    • 8.2.7 Pfizer
    • 8.2.8 BioMarin Pharmaceutical
    • 8.2.9 Sarepta Therapeutics
    • 8.2.10 Bluebird Bio
    • 8.2.11 CRISPR Therapeutics
    • 8.2.12 Vertex Pharmaceuticals
    • 8.2.13 Intellia Therapeutics
    • 8.2.14 REGENXBIO
    • 8.2.15 Audentes/Astellas Gene Therapies
    • 8.2.16 Rocket Pharmaceuticals
    • 8.2.17 Krystal Biotech
    • 8.2.18 Adaptimmune
    • 8.2.19 Iovance Biotherapeutics
    • 8.2.20 Cellectis